Status:

TERMINATED

Serotonin/Dopamine Antagonism of Cocaine Effect: 2 - 2

Lead Sponsor:

National Institute on Drug Abuse (NIDA)

Collaborating Sponsors:

VA Boston Healthcare System

Conditions:

Cocaine-Related Disorders

Eligibility:

All Genders

18-50 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to evaluate use of risperidone with cocaine abusers. Study measures incorporate an appropriate integration of behavioral and neurobiological indices.

Detailed Description

Risperidone in low doses is compared with placebo in a 6-week randomized trial. Subjects also receive supportive counseling. Outcome measure include rating of behavior, mood, drug abuse, global functi...

Eligibility Criteria

Inclusion Criteria:

Cocaine abuse or dependence

Exclusion Criteria:

Dependence on other drugs. Major psychiatric illness

Key Trial Info

Start Date :

January 1 1996

Trial Type :

INTERVENTIONAL

End Date :

March 1 1996

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00000310

Start Date

January 1 1996

End Date

March 1 1996

Last Update

January 16 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Brown University School of Medicine

Providence, Rhode Island, United States, 2906

Serotonin/Dopamine Antagonism of Cocaine Effect: 2 - 2 | DecenTrialz